USFDA Approves SHILPA MEDICARE's Joint Venture's First Oral Liquid Form of Imatinib for Certain Cancers

Shilpa Medicare's joint venture, Oncosol Limited, along with its partner Shorla Oncology, has announced that the USFDA has approved IMKELDI (imatinib oral solution), the first oral liquid form of imatinib to treat certain forms of leukemia and other cancers. This advanced liquid formulation of imatinib is designed to provide dosing accuracy and can help slow or prevent the growth of specific cancers, including chronic myeloid leukemia (CML), acute lymphoblastic leukemia, myelodysplastic syndrome /myeloproliferative disease (MDS/MPD), and gastrointestinal tumors (GIST). The approval is a significant milestone for Shilpa Medicare, which specializes in the Oncology therapeutic segment and introduces novel drugs focusing on patient convenience and compliance.